Arrowhead Pharmaceuticals Inc (BSP:A2RR34)
R$ 55.15 -0.75 (-1.34%) Market Cap: 7.79 Bil Enterprise Value: 4.65 Bil PE Ratio: 0 PB Ratio: 26.99 GF Score: 31/100

Arrowhead Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2026 / 03:30PM GMT
Operator

Good morning. Welcome everyone to the forty-fourth annual JPMorgan Healthcare Conference. My name is Matt Bannon, and I'm a banker here at JPM. I am very pleased to be introducing our first presenting company of the day, Arrowhead Pharmaceuticals, and presenting on behalf of Arrowhead, we have the President and CEO Chris Anzalone.

Before, we kick off, I'll just remind folks that we will have time for Q&A at the end of the session. So to ask a question, just raise your hand, we'll get you a mic, or you can ask it through the online portal, and I'll relay the question on your behalf. So, without further ado, Chris.

Christopher Anzalone
Arrowhead Pharmaceuticals Inc - Chairman of the Board, President, Chief Executive Officer

Well, thanks very much to JP Morgan for inviting us and thank you all for coming, and starting off this busy week. I'm sort of reminded of the, of a tsunami, right? When a tsunami comes, the wave doesn't come immediately, there is the tide recedes and so we are in that receding tide right now. And so good luck for the rest of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot